Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00877370 · ClinicalTrials.gov registry record · Phase 4
Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis
A Phase 4 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT00877370 is a Phase 4 study that has completed, run by University of Michigan. The registered enrollment target is 8 participants.
The verdict
NCT00877370, a Phase 4 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
Critically ill patients in the intensive care unit often receive continuous hemodialysis to treat their kidney failure. Ertapenem is an antibiotic often used in these patients. Continuous dialysis may remove ertapenem, putting patients at risk for inappropriate treatment of their infection. This study will determine how much ertapenem is removed by continuous hemodialysis.
Interventions
- DRUG ertapenem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00877370
The ClinicalTrials.gov registry entry for NCT00877370 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ertapenem is the first listed.
NCT00877370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00877370 about?
NCT00877370 is a clinical study titled "Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis". Critically ill patients in the intensive care unit often receive continuous hemodialysis to treat their kidney failure. Ertapenem is an antibiotic often used in these patients. Continuous dialysis may remove ertapenem, putting patients at risk for inappropriate treatment of their infection. This stu...
What is the current status of trial NCT00877370?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2009-02. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00877370?
The interventions under investigation include: ertapenem (DRUG).
Who is sponsoring clinical trial NCT00877370?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.